Bristol-Myers Squibb: 2Q26 wrap - beat and raise offsets clinical delays; PT to $61

Research evidence excerpt

Bristol-Myers Squibb: 2Q26 wrap - beat and raise offsets clinical delays; PT to $61

ipal research analyst(s) who prepared this report, members of the analysts' team, and members of their households

are not an officer, director, employee or advisory board member of the companies covered in the report.

• Our Compliance officer / Grievance officer is Ms. Rupal Talati, who can be reached at +91-22-68421451, or MUM-

BERNSTEIN-InCompliance@bernsteinsg.com / Scbin-investorgrievance@bernsteinsg.com

• The Research investor charter and Terms & Conditions of SCB India are available on its website and may be accessed at Sanford

C. Bernstein (India) Private Limited (https://bernsteinresearch.in/) for your reference.

• Disclaimer: Registration granted by SEBI, and certification from NISM, is in no way a guarantee of performance of the

intermediary or provide any assurance of returns to investors. Investments in securities market are subject to market risks. Read

all the related documents carefully before investing.

To our readers in Switzerland: This document is provided in Switzerland by or through Bernstein Autonomous LLP, and is

provided only to qualified investors as defined in article 10 of the Swiss Collective Investment Scheme Act (“CISA”) and related

provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations.

The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives

on the Independence of Financial Research issued by the Swiss Bankers Association (SBA) in January 2008.

To our readers in the Middle East: Bernstein Autonomous LLP, DIFC branch has its principal office at Gate Village 06, DIFC,

Dubai, UAE.